[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nausea-with-vomiting-chemotherapy-induced\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nausea-with-vomiting-chemotherapy-induced":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,70,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100374065","phase-4-bmt-08-a-comparative-effectiveness-study-of-transdermal-granisetron-to-ondansetron-100374065",false,"NCT04150614","BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron","BMT-08: A Comparative Effectiveness Study of the Efficacy and Safety of Transdermal Granisetron to Ondansetron in the Prevention of Nausea and Vomiting in Patients Undergoing Preparative Chemotherapy and Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Age 18-75 years at time of enrollment receiving either a preparative regimen and either an autologous or allogeneic stem cell transplant.\n* No vomiting ≤ 24 hours prior to registration\n* No treatment with an antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for ≤ 30 days' prior registration or planned during protocol therapy. No patients will be removed from these treatments for study enrollment purposes.\n* No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue antiemetic therapy). No patients will be removed from these treatments for study enrollment purposes.\n* No known hypersensitivity to granisetron\n\nExclusion Criteria:\n\n* Concurrent use of amifostine\n* Known hypersensitivity to granisetron patch or ondansetron\n* Patients with a history of long QT syndrome or Torsade de Pointes","ALL","18 Years","75 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.",[27],"Nausea With Vomiting Chemotherapy-Induced",[29],"Hematopoietic Stem Cell Transplantation","RECRUITING","2025-11-07",{"date":33,"type":34},"2025-11-12","ACTUAL",{"date":36,"type":34},"2020-05-14",{"date":38,"type":21},"2026-07",{"name":40,"class":41},"University of Illinois at Chicago","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100503055","implementation-of-personalized-medicine-for-optimal-drug-therapy-in-cancer-100503055","NCT05830279","Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer","Evaluating the Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer Patients: A Prospective Longitudinal Trial","Inclusion Criteria:\n\n* Age 18 years or older\n* Prescribed a chemotherapy medication\n* Currently taking one or more study medications (citalopram, escitalopram, venlafaxine, desvenlafaxine, codeine, oxycodone, hydrocodone, tramadol or ondansetron)\n\nExclusion Criteria:\n\n* Patients who are unable to complete study materials (surveys) with or without assistance, including non-English speaking patients\n* Patients receiving palliative care\n* Patients taking anti-depressants for reason other than depression or anxiety, i.e. hot flash (Only applies to antidepressant cohort)\n* Patients with preexisting major depressive disorder prior to cancer diagnosis (Only applies to antidepressant cohort)",{"count":51,"type":21},600,"OBSERVATIONAL","A prospective longitudinal cohort study that will assess the effect of a Personalized Medicine (PM) clinic recommendations on pharmacogenetic variation and\u002For interacting drugs on plasma drug exposure, effectiveness or toxicity of commonly used antidepressant, pain, and antiemetic medications in cancer patients. Such recommendations will entail genotype-guided treatment suggestions while also considering potential DDI, and will be provided to patients during their clinic visit, and referring physicians thereafter. Drug concentration and therapeutic effectiveness will be assessed before (baseline) and 6 months after recommendations have been provided. To assess effectiveness, patient-reported outcomes will be evaluated using validated scales for symptoms of depression, pain and chemotherapy-induced nausea\u002F vomiting\n\nThe investigators hypothesize that the pharmacogenetic variation and DDI, if applicable, determine steady state drug concentration and therapeutic response or toxicity of the investigated antidepressant, pain or antiemetic treatments at baseline, while there is a clinically significant reduction or absence of the effect 6 months after the PM clinic recommendations to referring physicians and patients.",[27,55,56],"Depression, Reactive","Cancer Pain",[58,59,60],"Personalized medicine","Pharmacogenetics","Therapeutic drug monitoring","2025-07-04",{"date":63,"type":34},"2025-07-09",{"date":65,"type":34},"2023-05-01",{"date":67,"type":21},"2026-04-30",{"name":69,"class":41},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":17,"enrollmentInfo":79,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":96,"locationsCount":98},"100582876","predict-chimio-or-radiation-induced-nausea-and-vomiting-in-childrenadolescents-treated-for-cancer-100582876","NCT06869005","Predict CHimio-or Radiation-induced NAusea and Vomiting in Children\u002Fadolescents Treated for Cancer","Prévoir Les NAusées Et Vomissements CHimio Ou Radio-induits Chez Les Enfants\u002Fadolescents Traités Pour Un Cancer","PaNACHE","Inclusion Criteria:\n\n* Treated in a pediatric onco-hematology center in the GOCE (Grand Ouest Cancer Enfant) inter-region;\n* Receiving chemotherapy or radiotherapy;\n* According to patient age :\n* Minor (under 18 years): At least one parent has been informed of the protocol and has not expressed opposition to the child's participation in the study\n* Adult (more than 18 years): Having received information about the protocol and not having expressed opposition to participating in the study\n\nExclusion Criteria:\n\n* Patients or legal representatives with French understanding difficulties.\n* Patients or legal representatives subject with legal protection (safeguard of justice, curatorship, guardianship) or deprived of liberty.","4 Years",{"count":80,"type":21},150,"Chemo- or radiation-induced nausea and vomiting (CRVN) is one of the most frequent and feared side effects.\n\nIt is a symptom that is few or not at all evaluated. There is a significant discrepancy between the perception of the CRVN symptom by caregivers and the patient's own experience.\n\nAt present, there is no real consensus to manage CRVN with medication, and CRVN relief is also the subject of heterogeneous practices. The importance of primary prevention of CRVN, before starting the first treatment sequence, has been highlighted to optimize the action of antiemetic treatments and limit the risk of anticipated nausea and vomiting (NV).\n\nThe investigators' objective is to objectively assess the risk of CRVN in children\u002Fadolescents treated for cancer (and thus effectively prevent this symptom).",[83,84],"Childhood Cancer","Nausea with Vomiting Chemotherapy-Induced",[83,86,87,88],"Chemo- or Radiation-induced Nausea and Vomiting (CVRN),","BARF scale","PaNACHE score","NOT_YET_RECRUITING","2025-03-06",{"date":92,"type":34},"2025-03-11",{"date":94,"type":21},"2025-03",{"date":38,"type":21},{"name":97,"class":41},"Rennes University Hospital",5,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100522304","ondanstron-weekly-vs-every-3-weeks-for-prevention-of-nausea-and-vomiting-induced-by-chemotherapy-combined-with-pd-1-blockade-100522304","NCT06080880","Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade","Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade：an Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years, no gender limit;\n2. Pathologically or cytologically confirmed malignant solid tumors;\n3. Scheduled to receive cisplatin-based chemotherapy combined with PD-1 blockade；\n4. TPS \\> 1 %(PD-1);\n5. Adequate hematological function (leucocyte count ≥ 4000\u002FμL \\[to convert to ×109\u002FL,multiply by 0.001\\], hemoglobin ≥ 9.00 g\u002FdL \\[to convert to grams per liter, multiply by 10\\], and platelet count ≥ 100 × 103\u002FμL \\[to convert to ×109\u002FL, multiply by 1\\]);\n6. Hepatic function (alanine aminotransferase and aspartate aminotransferase ≤ 2.0 times the upper limit of the reference ranges), and renal function (creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m2 \\[to convert to millimeters per second per meter-squared, multiply by 0.0167\\])；\n7. Estimated survival time \\> 6 months；\n8. ECOG 0-1 points；\n9. Participants being informed and signed written consents.\n\nExclusion Criteria:\n\n1. Nausea or vomiting caused by reasons except for chemotherapy and PD-1 blockade;\n2. Participants with other malignant tumors history previously;\n3. Inability to read, comprehend, and finish questionnaires;\n4. Allergic to the drugs included in this study.\n5. Administered drugs with antiemetic activity within the 24 hours before receiving the first dose of study medication.",{"count":107,"type":21},98,[109],"NA","The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.",[27],[113,114,115],"Chemotherapy-induced nausea and vomiting","PD-1 blockade","Ondanstron","2024-02-28",{"date":118,"type":34},"2024-02-29",{"date":120,"type":34},"2023-12-01",{"date":122,"type":21},"2027-11",{"name":124,"class":41},"Hubei Cancer Hospital"]